[PDF] Top 20 Un Saber Que No Se Sabe. La Experiencia Analítica [Maud Mannoni]

... of evidence that is generated year after year in the field of oncology, publications that review and collect the most relevant data help profes- sionals involved in the management of patients to keep ... See full document

... with advanced renal cell carcinoma who have failed prior cytokine-based therapy or are considered unsuitable for such ...real-life practice. This study aims to conduct a literature ... See full document

... clear cell hist- ology who were treated with pazopanib as first-line TKI therapy in 2012 were retrospectively ...with pazopanib was solely at the discretion of the treating ...in clinical ... See full document

... metastatic renal cell carcinoma (mRCC) has markedly improved over the last few years with the introduction of several targeted agents in clinical ...the clinical benefit of these ... See full document

... Evidence review: Everolimus was approved for second- and third-line therapy in patients with advanced RCC according to the results of a Phase III pivotal trial that demonstrated a benefit in median ... See full document

... between pazopanib and BSC in the treatment-naive population suggest that the benefit of pazopanib is similar regardless of whether the patient had previously been randomized to placebo and then progressed ... See full document

... systematic review, it is clear that all the evidence for the use of cabozantinib for untreated mRCC patients comes from a single Phase II ...of evidence required to definitely change clinical ... See full document

... The management of renal cell carcinoma (RCC) has undergone significant changes during the past 10 years, with the treatment of metastatic RCC undergoing the most radical ...the ... See full document

... the management and treatment of advanced ...the clinical landscape of the ...and evidence is eagerly awaited to inform clinical ...for advanced RCC are on the hor- ...appropriate ... See full document

... the evidence review group report to project 4 distinct health states: stable disease without adverse events, stable disease with adverse events, pro- gressive disease, and ... See full document

... of pazopanib, an oral multitargeted tyrosine kinase inhibitor which potently targets vascular endothelial growth factor receptors 1–3, platelet-derived growth factor, and c-kit, six agents are now available for ... See full document

... experience in Saudi Arabia in implementing a multidisciplinary approach provides a valuable model for consideration and wider adoption. in major Saudi tertiary hospitals, a tumor board, consisting of urologists or ... See full document

... for renal cell carcinoma), disease free survival (time between treatment and the first metastasis or local recurrence) and overall survival (time between diagnosis and death irrespective of cause) ... See full document

... The surgical approach to patients with IVC involvement is mostly dictated by the cephalad extent of the thrombus. The choice of incision (midline, subcostal or chevron) remains the pref- erence of the individual surgeon. ... See full document

... Statistical analysis was performed with the Statistical Package of the Social Sciences (SPSS), version 17.0. The primary endpoints of the study were DFI be- tween resection of primary renal tumour and presen- ... See full document

... Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups ...with pazopanib (median ...with pazopanib had a higher incidence of ...to pazopanib in the first-line ... See full document

... both renal veins were ...right renal vein. The renal vein on the unaffected side was also ...the renal vein on the affected side was ...affected renal vein at its point of drainage into ... See full document

... The CELESTIAL trial was a double-blinded, randomized phase III trial that compared cabozantinib with placebo in previously treated, advanced HCC patients who were not amenable to curative treatment. 33 707 HCC ... See full document

... with pazopanib having some inhibitory property that other agents ...Alternatively, pazopanib may have pharmacodynamic or pharmacokinetic properties that favor its ...the clinical trials undertaken ... See full document

... or pazopanib, to enable further evaluation of the safety and efficacy of such combinations in patients with ...plus pazopanib combination regimens, or between either combination therapy and any ... See full document